Principle of the engineered probiotic TYS8500 as a live biotherapeutic for phenylketonuria (IMAGE)

Science China Press

Principle of the engineered probiotic TYS8500 as a live biotherapeutic for phenylketonuria

Caption

Patients with phenylketonuria are unable to metabolize phenylalanine in the liver as healthy people do. They metabolize phenylalanine in the intestine alternatively through oral administration of the engineered probiotic TYS8500.

Credit

©Science China Press

Usage Restrictions

Use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.